The US Food and Drug Administration (FDA) has approved Sunovion Pharmaceuticals' (Sunovion) antiepileptic drug (AED) Aptiom (eslicarbazepine acetate) for the treatment of partial-onset seizures in patients with epilepsy. According to the ...
Tags: FDA, Sunovion, partial-onset seizure, epilepsy
Health Canada has accepted to review Sunovion Pharmaceuticals Canada's (Sunovion) new drug submission (NDS) for eslicarbazepine acetate for use as a once-daily adjunctive therapy for the treatment of partial-onset seizures in patients aged ...
US-based Blend Therapeutics has appointed Mark Iwicki as its president, chief executive officer and a member of the board of directors. Iwicki comes with more than 23 years of experience in the pharmaceutical industry with experience in ...
Tags: Blend Therapeutics, CEO, Iwicki, drug development
The FDA has approved the stretched dose range for Sunovion Pharmaceuticals' Latuda for the treatment of patients with schizophrenia. After the review of the supplemental new drug application (sNDA), which was submitted in June 2011, ...
Tags: FDA, Schizophrenia, dose range for Latuda
Watson Pharmaceuticals has introduced authorized generic version of Xopenex (levalbuterol HCl) inhalation solution and begun the shipment of the product. Xopenex inhalation solution indicated for the treatment or prevention of ...
Tags: Xopenex inhalation solution, bronchospasm, Sunovion Pharmaceuticals
Eisai has introduced the insomnia drug, Lunesta (eszopiclone), in Japan. Discovered and developed by Sunovion Pharmaceuticals, Lunesta is a non-benzodiazepine type GABAA agonist (non-benzodiazepine sedative hypnotic). In a Phase II/III ...
Sunovion Pharmaceuticals has launched Zetonna(ciclesonide)Nasal Aerosol,74 mcg once-daily,in the US,which is used to treat allergic rhinitis(AR),also known as hay fever or nasal allergies. Zetonna is also used to treat symptoms ...
Mylan has reached a settlement in a patent litigation suit filed by Sunovion Pharmaceuticals concerning Mylan Specialty's abbreviated new drug application for Levalbuterol Hydrochloride (HCl) Inhalation Solution, 0.31mg/3 mL, 0.63mg/3 mL, ...
Tags: Sunovion Pharmaceuticals, Medicine
Sunovion Pharmaceuticals has submitted two supplemental new drug applications (sNDAs) to the FDA seeking approval for the use of LATUDA (lurasidone HCl) as monotherapy and adjunctive therapy in adult patients with depressive episodes ...
Tags: FDA, sNDA, atypical class of drugs, bipolar depression
Watson Pharmaceuticals said Sunovion Pharmaceuticals has challenged Watson Laboratories filing of Abbreviated New Drug Application(ANDA)with the US Food and Drug Administration(FDA)seeking approval for marketing Levalbuterol Tartrate ...
Tags: Sunovion, FDA, Watson Laboratories
Sunovion Pharmaceuticals is set to launch Zetonna (ciclesonide) nasal aerosol, a non-aqueous, dry nasal aerosol spray for allergic rhinitis in the third quarter of 2012 in the US. The 74mcg once-daily product is indicated for the ...
Tags: Sunovion Pharmaceuticals, Medicine, Zetonna nasal aerosol